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Abstract
Designing a vehicle for local delivery of proteins using intra-articular route is an attractive 
option to minimize the adverse effects associated with systemic exposure and to maximize the 
efficacy. Slowly-dissolving silylated micro-particles are designed with specific size and shape that 
are capable of extending the retention time of a model protein (BSA) in the murine knee joint. No 
cytotoxicity is observed for the reconstituted formulation when tested against synovial fibroblasts 
and RAW macrophages.
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Local treatment of arthritis is an attractive option when the symptoms are restricted to 
individual joints. However, benefits of local treatment can be limited by poor retention of the 
drug in the joint.[1] The principal advantage of local delivery is that only a minimal amount 
of drug is required to exert the desired pharmacological activity thereby reducing drug 
exposure to inappropriate sites.[2–4] Furthermore, due to lack of vascularity in articular 
cartilage, regional administration is more beneficial compared to administration into the 
systemic circulation.[5] Specifically, for protein based drugs with low bioavailability by other 
routes, regional administration through the intra-articular (i.a.) route is a valuable option.[6] 
It is known that entry of macromolecules into the synovial fluid from systemic circulation is 
inversely proportional to their molecular weight,[4] and therefore the higher the molecular 
weight of the therapeutic, the more difficult it is to systematically deliver it to the joint. 
According to Mitragotri and Yoo,[7] carrier systems that release the drug in a controlled 
manner in the synovial area and are rationally designed based on physiochemical properties 
of the drug and pathophysiological characteristics of the disease are greatly needed for 
treating arthritis. In this work, possibility of using slowly-dissolving silylated bovine serum 
albumin (BSA) particles (functionalization and characterization details can be found 
elsewhere),[8] as a carrier for i.a. delivery is investigated. We demonstrate that these silylated 
particles can be lyophilized in a non-aqueous mixture to confer physiochemical stability to 
the formulation. Cell viability study of murine macrophages and synovial fibroblasts [9] 
confirm that functionalization does not induce cytotoxicity in the formulation. Upon 
reconstitution of the lyophilized formulation, particles are then delivered to the mouse knee 
joint using i.a. route to determine their in vivo retention.
Half-lives (t1/2) of soluble proteins in the joint of different animal models have been 
extensively studied. Larsen et al.[2] compiled a list for t1/2 of various molecules in joints of 
non-murine models. Clearance of native BSA from rabbit joint is relatively fast with t1/2 of 
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only 3.91 hours (hr).[10] Based on the experiments of van den Berg and van de Putte,[11] 
negatively charged native BSA shows no affinity for cartilage and high amounts of 
antibodies are needed for its retention in the mice joint. On the contrary, the retention of 
cationic BSA in non-immune mice joint is very high. Moreover, chronic joint inflammation 
in immune mice (antigen + Freund’s complete adjuvant (FCA) injected into flank skin and 
the footpads of the forelegs + intraperitoneal injection of heat-killed Bordetella Pertussis 
organisms as an additional adjuvant) only developed after i.a. administration of cationic 
antigens (methylated BSA, amidated BSA) but not native BSA.[12] For immune mice (BSA
+FCA) even with the administration of a booster (BSA+FCA), the retention of native BSA 
in the joint is still low. Experiments of van Lent et al.[13] with radiolabeled proteins in mice 
confirmed that both charge and size of the protein are important factors for determining the 
penetration and localization in the joint. Moreover, upon i.a. injection of radiolabeled native 
human immunoglobulin G (IgG) and BSA, less than 1% of the injected dose can be detected 
in the joint after 24 hr. Lymphatic drainage is expected to be the primary mechanism 
responsible for the clearance of soluble form of proteins from the joint cavity,[4,14–16] and 
experimentally it has been observed that the clearance times of anionic native proteins with 
disparate molecular weights (IgG and BSA) are of the same order.[12–14]
Several researchers have used particulate based carrier systems with variety of sizes and 
compositions to investigate their potential in increasing the joint retention time or reducing 
inflammation. Horisawa et al.[17] have studied the size effect of particles made from poly 
(D,L-lactide-co-glycolide) (PLGA) in rats by comparing the retention of 265 nm and 26.5 
μm particles. Liggins et al.[18] prepared paclitaxel loaded PLGA, poly (L-lactic acid), and 
poly (caprolactone) with different sizes to investigate biocompatibility and efficacy in 
rabbits for treatment of inflammation. Butoescu et al.[19] have used magnetic PLGA nano-
particles for delivery of dexamethasone 21-acetate to the mouse joint. Nishide et al.[20] have 
studied in vivo fate of micro-spheres made of D,L-lactic acid oligomers of different 
molecular weights and sizes. Brown et al.[21] have tested gelatin plus chondroitin-6-sulfate 
micro-spheres for delivery of labeled catalase and albumin into mouse joint. Block 
copolymers have been used to tether interleukin-1 receptor antagonist (IL-1Ra) to the 
particles for joint retention study in rats.[22] Inoue et al.[23] measured the residual dose of 
basic fibroblast growth factor contained in glutaraldehyde (GA) crosslinked gelatin micro-
spheres.
Review by Gerwin et al.[24] gives an in-depth view on the i.a. delivery route including the 
micro and nano-particulate systems. Beside the polymeric and gelatin based systems, 
albumin particles have been used as a potential carrier for delivery of therapeutics. The 
advantage of albumin particulate system is lack of toxicity and biodegradation into natural 
products.[25] Human serum albumin (HSA) has been used as a vehicle for targeted delivery 
of methotrexate.[26] Heat-stabilized (150 °C for 40 hr) rabbit serum albumin (RSA) micro-
spheres have been prepared for delivery of steroids with t1/2 of 62.5 hr.[27] BSA has also 
been studied as a viable injectable biodegradable system for sustained release of 
progesterone in rabbits,[28] and as a matrix for delivery of dexamethasone,[29] diclofenac 
sodium,[30] and naproxen sodium.[31] Ratcliffe et al.[32] intra-articularly delivered radio-
labeled RSA using GA crosslinked micro-spheres and noticed t1/2 of 3 days. The authors 
also observed that particles made from RSA cause minimal histological change in rabbit 
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synovium and thus are good candidates for a biocompatible delivery vehicle.[33] Two major 
problems with GA crosslinked and heat stabilized albumin particles are formation of 
uncleavable crosslinks and loss of molecular secondary structure upon denaturation which 
proves to be detrimental to the protein functionality. Moreover, the shapes of these fabricated 
particles are restricted to simple and basic geometries like spheres. Size and shape of the 
particles can both play important roles in triggering an inflammatory reaction and it has been 
demonstrated that irregularly shaped particles promote tissue inflammation when compared 
to round-shaped objects.[6]
This communication focuses on developing a particulate albumin system for delivering 
proteins using i.a. route by rectifying the above-mentioned shortcomings, and then compares 
the joint retention of the slowly-dissolving particles with that of a protein solution. Stability 
is conferred to the particles with diisopropyldichlorosilane (DIDCS) as a crosslinking agent 
that retains the secondary structure of the molecule while shape and size of the particles is 
precisely controlled with Particle Replication in Non-wetting Templates (PRINT) to prepare 
micro-toroids with rectangular cross-section.[8]
Upon fabricating micro-particles containing 55.7 wt % BSA (model protein), 43.1 wt % 
lactose, and 1.2 wt % glycerol with PRINT platform, they are functionalized with DIDCS to 
make them slowly-dissolving in aqueous medium. DIDCS which belongs to the family of 
dichlorosilanes reacts with BSA and glycerol to make the particles slowly dissolving by 
introducing a silyl group in place of a labile hydrogen atom and combining molecules 
together. The scanning electron microscopy (SEM) images of Alexa Fluor 680 conjugated 
BSA loaded micro-particles are shown in Figure 1.A and 1.B. To confer storage stability and 
prepare a reconstitutable powder, particles are freeze-dried from a mixture of poly (vinyl 
pyrrolidone) (PVP) and tert-butanol (TBA). According to Cingolani et al.[34] TBA can 
stabilize proteins by decreasing their solubility and inducing salting-out and has been used in 
pure form by Ni et al.[35] for freeze-drying of an antitumor drug. Use of TBA allows us to 
prepare stable dry particles with minimal aggregation that are not exposed to water prior to 
reconstitution. Furthermore, addition of PVP prevents the aggregation of the particles during 
the lyophilization stage by acting as a bulking agent (Figure 1.C). These particles (loaded 
with Alexa Fluor 555 conjugated BSA) can then be uniformly dispersed in the reconstitution 
media composed of PBS+0.1% w/w Tween 80 (Figure 1.D and 1.E). The rational for using 
Tween 80 in the formulation is to improve the dispersibility of the particles and is based on 
its low cytotoxicity.[36] Functionalized particles freeze-dried in TBA+5% w/v PVP (Figure 
1.F) retain their shape after a hydration/dehydration cycle of an environmental SEM (Figure 
1.G) with PVP easily dissolved to recover the individual particles.
The longer the reaction (rx) time of the particles with DIDCS, the slower is their dissolution 
rate.[8] In Figure 2.A–2.H effect of exposure of the particles to the reconstitution medium 
post lyophilization from freeze-drying medium (TBA+5% w/v PVP) is evaluated with SEM. 
The 24 hr silylated particles are highly stable in aqueous medium with very slow dissolution 
rate. After spending 4 days in reconstitution medium, the surface morphology of this set of 
particles changes (Figure 2.C and 5.G.) and then 4 days later they are very soft and 
deformable (Figure 2.D and 2.H). However, when the particles are silylated for only 12 hr, 
even a brief exposure (10 minutes) to the reconstitution medium results in severe structural 
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changes (Figure 2.B and 2.F). Unfunctionalized dry particles that were not exposed to the 
reconstitution medium are also shown for comparison (Figure 2.A and 2.E). These 
observations are consistent with the faster dissolution rate of 12 hr silylated particles when 
compared to the particles silylated for 24 hr,[8] and qualitatively show the structural changes 
associated with the exposure of the silylated particles to the reconstitution medium. The 
relative size of the particles is compared with the diameter of the needle used for the i.a. 
injections in Figure 2.I–2.K.
Activated synovial fibroblasts play an important role in arthritis,[37] and it is known that 
synovial fibroblasts are responsible for particle ingestion and uptake after i.a. delivery.[38,39] 
Brown et al.[21] evaluated the cytotoxicity of their particles against synovial fibroblasts 
extracted from arthritic patients. RAW macrophages have also been used to evaluate the 
cytotoxicity of nano-particles for i.a. delivery.[22] Viability of the cultured (flow cytometry 
data in Figure S1) synovial fibroblasts (Figure 2.L) and RAW macrophages (Figure 2.M) 
were determined, once they were incubated with different combination of ingredients used 
in preparation of the injectable formulation (data shown in Figure S2). Figure 2.L, 2.M show 
the results for PVP and Tween 80 which serve as a measure for evaluating the inherent 
cytotoxicity of the reconstitution medium. In the case of synovial fibroblasts, no cytotoxicity 
for unfunctionalized particles could be detected whereas there is a reduction of viability for 
RAW macrophages (Figure 2.M). This reduction might be attributed to the nitric oxide 
production due to stimulation of macrophages by BSA.[40] No reduction of viability was 
observed for functionalized particles.
Upon optimizing the i.a. injection (Figure S3), Alexa Fluor 680 conjugated BSA loaded 
particles (Table S1) were intra-articularly delivered to the knee joint of mice. Figure 3 
juxtaposes the time course clearance of the functionalized particles with that of the soluble 
form (unfunctionalized) for the group of animals studied (Figure S4). The rate at which the 
radiant efficiency (calibrated in Figure S5) and fractional fluorescence remaining in the joint 
diminish is notably faster for the unmodified form compared to the functionalized particles.
The areas under the curve for 24 hr silylated and unmodified particles (Figure S6) were 
calculated as 5.16E+9 and 2.91E+9 [p/s/cm2/sr][hr]/[μW/cm2], respectively. Furthermore, 
the half-lives of these samples were determined to be 19.4 and 4.4 hr. Figure 2.N–2.Q 
histologically evaluate the Alexa Fluor 680 conjugated BSA particles in the joint 12 hr post 
injection upon isolation of the knee (Figure S7). Particles (red) could be located in different 
positions inside the joint cavity 12 and 36 hr after injection (Figure S8 and S9). Moreover, 
infiltration of cellular components (blue) stained with DAPI (4′,6-diamidino-2-phenylindole) 
in the joint cavity can be seen in Figure 2.P and 2.Q in the close proximity of the particle 
aggregates. These figures suggest that some of the particles remain in the synovial cavity 
while slowly dissolving (releasing their protein content) and some are associated with the 
synovial membrane and thus cleared throughout the course of our in vivo experiment. Figure 
2.O and Figure 2.Q are confocal images obtained from 3D rotation of Figure 2.N and 2.P, 
respectively. (Video S1 and S2)
In this communication, we demonstrated that the dissolution of the silylated particles is 
accompanied by surface morphological changes as observed with SEM. Cell viability 
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studies on RAW macrophages and synovial fibroblasts confirmed that the functionalization 
of particles does not attribute cytotoxicity to the particles. Half-life of the fluorescent labeled 
BSA after incorporation into the 24 hr silylated particles is 4.4 times and the averaged area 
under curve for fluorescent signal versus time in the joint is 1.78±0.39 times of that of the 
unmodified soluble protein. Although Rodnan and Maclachlan,[14] did not observe any 
differences between the rates of clearance of heterologous albumin (HSA) and homologous 
albumin (RSA) in normal rabbit joint, fabricating particles from homologous albumin is 
recommended to safely neglect the antigenic cause of clearance. Immunogenicity and charge 
state of the silylated BSA used as a carrier in the particle composition is an important factor 
when preparing an injectable formulation for arthritis and should be diligently studied. 
According to Lee et al.[28] injectable beads prepared by crosslinking BSA under mild 
conditions using GA should yield a non-immunogenic and biodegradable device for drug 
delivery. Silylation of BSA particles may change or create new epitopes on the protein, 
which can induce antibodies against the particle carriers and result in fast clearance of 
carriers. However, our imaging data suggest that the particles are retained in joint space for a 
much longer time than soluble BSA. Although we do not expect generation of antibodies 
against homologous albumin, a full evaluation of the immunogenicity of the particles post 
silylation in future will help us better understand the properties of this system. Charge state 
determination by isoelectric focusing helps elucidate the charge interaction of the particles 
and released BSA molecules with the articular cartilage.[12]
Potential use of di-tert-butyldichlorosilane (with bulkier side groups) in extending the 
retention time of the particles needs to be further investigated.[41] Whereas, it is beyond the 
scope of this communication, PRINT technology proves to be helpful for systematically 
elucidating the role of shape and size in retention/clearance of the particles from the joint. 
Flexibility of PRINT technology to engineer non-spherical geometries has been discussed 
elsewhere.[42,43] Other BSA containing particles prepared with PRINT platform can be used 
to investigate the effect of shape on particle retention (Figure S10).
Experimental Section
The detailed experimental procedures are available in the Supporting Information.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Particles fabricated with PRINT platform at two different magnifications. A.×15k-scale bar 
= 3.00 μm. B.×1.1k-scale bar = 50.0 μm. C. Dry cake of 24 hr functionalized particles freeze 
dried from 5% w/v PVP-TBA-scale bar = 10 μm. D. particles dispersed in 0.1% w/w Tween 
80 in PBS (high magnification)-scale bar = 10 μm. E. particles dispersed in 0.1% w/w 
Tween 80 in PBS (low magnification)-scale bar = 20 μm. (Excitation: 543 nm, Long pass 
filter: 560 nm) Hydration cycle effect studied with Environmental SEM. F. Particles freeze 
dried in 5% PVP+TBA prior to cycle-scale bar = 50 μm. G. 24 hr silylated particles freeze 
dried in 5% w/v PVP+TBA after the cycle-scale bar = 30 μm.
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An unfunctionalized particle not exposed to PBS (A.×30k magnification-scale bar = 1.00 
μm, E.×100k magnification-scale bar = 500 nm). Silylated for 12 hr and exposed to PBS
+0.1% w/w Tween 80 for 10 minutes (B.×30k magnification, F.×100k magnification). 
Silylated for 24 hr and exposed to PBS+0.1% w/w Tween 80 for 4 days (C.×30k 
magnification, G.×100k magnification). Silylated for 24 hr and exposed to PBS+0.1% w/w 
Tween 80 for 8 days (D.×30k magnification, H.×100k magnification). Relative size of the 
particles compared to 30G ½ needle (176 μm in diameter) used for i.a. injections (I.×90-
scale bar = 500 μm J.×400-scale bar = 100 μm K.×1k-scale bar = 50.0 μm) Percent cell 
viability of different compositions at 1 mg/mL for 12 and 24 hr silylated samples (L. 
synovial fibroblasts, M. RAW macrophages). Functionalized Alexa Fluor 680 conjugated 
BSA loaded particles 12 hr post injection into the murine knee joint cavity. N. Red+Blue
+DIC-scale bar = 10 μm. O. Red+Blue, 3D confocal rotation. Presence of cellular 
components in the joint cavity P. Red+Blue+DIC-scale bar = 10 μm. Q. Red+Blue, 3D 
confocal rotation. (Red: Alexa Fluor 680 conjugated BSA Excitation: 639 nm Long pass 
filter: 640 nm, Blue: DAPI Excitation: 405 nm, Band pass filter: 420–475 nm + 500–610 
nm, DIC: Differential Interference Contrast, rx: reaction)
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Time course clearance of the functionalized particles containing Alexa Fluor 680 conjugated 
BSA compared to the intact particulate formulation at 2, 4, 6, 8, 12, 20, 24, 48, and 72 hr 
post injection as measured by radiant efficiency emanating from the knee joint. (n=4, rx: 
reaction)
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